Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin, Dapagliflozin, and Metformin/Pioglitazone in Newly Diagnosed Type 2 Diabetes
NCT05591235Phase 3Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of metformin, dapagliflozin, pioglitazone in type 2 diabetes mellitus (T2DM), insulin resistance (IR), sponsored by Nanjing First Hospital. Status: unknown.
02
Drugs
metformindapagliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)insulin resistance (IR)
Beyond the preview
Go deeper on NCT05591235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05591235.